PROVECTUS
About
At Provectus, we are obsessed with technologies that impact the future of the whole of humanity. Just imagine: AI for curing eye diseases, ML for making factories safe for workers, preventing pandemic spreading, etc. It’s not about the future, it’s about the products we’ve already developed with ProvectusTeam.
Updates & Highlights
Provectus reports oral PV-10 bladder cancer study results By Investing.com
Provectus reports oral PV-10 bladder cancer study results By Investing.com
Investing.com Nigeria · 3 days ago
PROVECTUS BIOPHARMACEUTICALS, INC. 1Q 2026: Revenue $0 EPS $0— 10-Q Summary
PROVECTUS BIOPHARMACEUTICALS, INC. 1Q 2026: Revenue $0 EPS $0— 10-Q Summary
TradingView · 7 days ago
Provectus: Q1 Earnings Snapshot
Provectus: Q1 Earnings Snapshot
marketscreener.com · 7 days ago
Recent Openings
View all 4 jobsSenior ML Engineer (LLMs, AWS)
En remoto, ES
Senior Generative AI Engineer (LLMs)
ES
Middle/Senior ML Engineer (GenAI)
TOS, IT
Middle/Senior ML Engineer (GenAI)
En remoto, ES
All Jobs
Senior ML Engineer (LLMs, AWS)
En remoto, ES
Senior Generative AI Engineer (LLMs)
ES
Middle/Senior ML Engineer (GenAI)
TOS, IT
Middle/Senior ML Engineer (GenAI)
En remoto, ES
Culture & Mission
Benefits & Perks
Health Insurance
Medical, dental & vision
Remote Work
Work from anywhere flexibility
Learning Budget
Professional development
Generous PTO
Paid time off
Competitive Salary
Market-rate compensation
Equity/Stock Options
Ownership in the company
Tech Stack
Core Values
Innovation
Pushing boundaries in AI/ML technology
Collaboration
Working together to achieve more
Excellence
Striving for the highest quality
Impact
Making a difference in the world
Office Locations
Team
Are you on the team at Provectus?
Claim this company page to verify ownership, edit details, and respond to applicants.
Claim this company →News & Press
20 recentProvectus reports oral PV-10 bladder cancer study results By Investing.com
Provectus reports oral PV-10 bladder cancer study results By Investing.com
Investing.com Nigeria · 3 days ago
PROVECTUS BIOPHARMACEUTICALS, INC. 1Q 2026: Revenue $0 EPS $0— 10-Q Summary
PROVECTUS BIOPHARMACEUTICALS, INC. 1Q 2026: Revenue $0 EPS $0— 10-Q Summary
TradingView · 7 days ago
Provectus: Q1 Earnings Snapshot
Provectus: Q1 Earnings Snapshot
marketscreener.com · 7 days ago
Provectus: Q1 Earnings Snapshot
Provectus: Q1 Earnings Snapshot
crossville-chronicle.com · 7 days ago
Provectus: Q1 Earnings Snapshot
Provectus: Q1 Earnings Snapshot
GreenevilleSun.com · 7 days ago
Provectus Biopharmaceuticals (PVCT) warns on going concern amid Q1 2026 loss
Provectus Biopharmaceuticals (PVCT) warns on going concern amid Q1 2026 loss
Stock Titan · 7 days ago
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
marketscreener.com · 7 days ago
Provectus Biopharm (PVCT) CEO converts 8% note into equity
Provectus Biopharm (PVCT) CEO converts 8% note into equity
Stock Titan · 15 days ago
How many employees work at Provectus IT?
How many employees work at Provectus IT?
Revelio Labs · 15 days ago
Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis
Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose Subsidiary and Rose Bengal Sodium in Infectious Ke...
ChartMill · 17 days ago
[ARS] PROVECTUS BIOPHARMACEUTICALS, INC. SEC Filing
[ARS] PROVECTUS BIOPHARMACEUTICALS, INC. SEC Filing
Stock Titan · 21 days ago
Provectus Biopharmaceuticals (PVCT) seeks approval for reverse split and director slate
Provectus Biopharmaceuticals (PVCT) seeks approval for reverse split and director slate
Stock Titan · 21 days ago
IFC mulling 20 mln euro investment in Croatia's Provectus SEE Fund II
IFC mulling 20 mln euro investment in Croatia's Provectus SEE Fund II
SeeNews · 21 days ago
Provectus (NASDAQ: PVCT) CEO converts 8% note into Series D-1 equity
Provectus (NASDAQ: PVCT) CEO converts 8% note into Series D-1 equity
Stock Titan · 23 days ago
Provectus Plans Headquarters Move to Historic Perkins Place
Provectus Plans Headquarters Move to Historic Perkins Place
The Globe and Mail · 30 days ago
Provectus Plans Headquarters Move to Historic Perkins Place
Provectus Plans Headquarters Move to Historic Perkins Place
TipRanks · about 1 month ago
Provectus Biopharmaceuticals (PVCT) Eps Diluted (TTM)
Provectus Biopharmaceuticals (PVCT) Eps Diluted (TTM)
Zacks Investment Research · about 1 month ago
Provectus Biopharmaceuticals to Hold 2026 Annual Meeting at Planned Perkins Place HQ
Provectus Biopharmaceuticals to Hold 2026 Annual Meeting at Planned Perkins Place HQ
TradingView · about 1 month ago
Provectus Biopharmaceuticals to Host 2026 Annual Stockholders Meeting at New Knoxville Headquarters
Provectus Biopharmaceuticals to Host 2026 Annual Stockholders Meeting at New Knoxville Headquarters
geneonline.com · about 1 month ago
Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of
Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of
GlobeNewswire · about 1 month ago